Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study

Philip N Newsome,Melissa Palmer,Bradley Freilich,Muhammad Y Sheikh,Aasim Sheikh, Harry Sarles,Robert Herring,Parvez Mantry,Zeid Kayali,Tarek Hassanein,Hak-Myung Lee,Guruprasad P Aithal

Journal of Hepatology（2020）

引用 48|浏览47

暂无评分

摘要

•Volixibat decreased serum C4 (bile acid synthesis biomarker) and cholesterol, indicating adequate target engagement.•Volixibat had no therapeutic impact on steatosis or liver injury in NASH.•Treatment-emergent adverse events were mainly of mild or moderate grade.•No serious adverse events were attributed to volixibat.

查看译文

关键词

Non-alcoholic fatty liver disease,Non-alcoholic steatohepatitis,Steatosis,Alanine aminotransferase,ASBT inhibitor,Humans,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要